KB-R7785 是一种基质金属蛋白酶 (MMP) 抑制剂,对 MMP-1、MMP-3 和 MMP-9 的 IC50 值分别为 3.0 nM、1.9 nM 和 3.9 nM,可抑制 MMP 活性与 TNF-α 的释放,并能减轻脑梗死形成、改善胰岛素敏感性、降低血浆葡萄糖与胰岛素水平、预防致死性内毒素休克及 GVHD 相关病理改变。
产品编号: MS-V90037 纯度: 99.90% CAS No.: 168158-16-5 分子式: C18H27N3O4 分子量: 349.42
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

KB-R7785 是一种基质金属蛋白酶 (MMP) 抑制剂,对 MMP-1、MMP-3 和 MMP-9 的 IC50 值分别为 3.0 nM、1.9 nM 和 3.9 nM,可抑制 MMP 活性与 TNF-α 的释放,并能减轻脑梗死形成、改善胰岛素敏感性、降低血浆葡萄糖与胰岛素水平、预防致死性内毒素休克及 GVHD 相关病理改变。

生物实验数据

生物活性 KB-R7785 is a matrix metalloproteinase (MMP) inhibitor with IC50 values of 3.0 nM, 1.9 nM, and 3.9 nM for MMP-1, MMP-3, and MMP-9, respectively; it inhibits MMP activity and TNF-α release, and can attenuate cerebral infarction, improve insulin sensitivity, reduce plasma glucose and insulin levels, and prevent lethal endotoxic shock and GVHD-related pathological changes.
IC50 & Target

MMP-3

1.9 nM ()

MMP-1

3 nM ()

MMP-9

3.9 nM ()

体外研究
(In Vitro)

KB-R7785 可强效抑制人 MMP-1、MMP-3 和 MMP-9,其 IC50 值分别为 3.0 nM、1.9 nM 和 3.9 nM。
KB-R7785 (1-10 μM; 72 h) 可呈剂量依赖性抑制 LPS (MS-X54539) 刺激的 THP-1 细胞释放 TNF-α。
KB-R7785 (1-10 μM; 24 h) 可剂量依赖性地抑制 hFasL/L5178Y 细胞释放 FasL。
KB-R7785 (0.625-10 μM; 48 h) 可剂量依赖性地抑制经热灭活单核细胞增生李斯特菌刺激的未致敏 C57BL/6 小鼠脾细胞产生可溶性 TNF-α,但不影响 IFN-γ 的产生,仅以非剂量依赖性方式部分影响 IL-10 的产生。

ELISA Assay

Cell Line: human monocytic leukemia THP-1 cells
Concentration: 1-10 μM
Incubation Time: 72 h
Result: Inhibited TNF-α release from LPS-stimulated THP-1 cells in a dose-dependent manner, with similar efficacy to KB-R8301.
Reduced TNF-α release to approximately 30% of the control level at 10 μM.
体内研究
(In Vivo)

KB-R7785 (30-100 mg/kg;皮下注射) 可剂量依赖性地减少永久性局灶性脑缺血小鼠模型的脑梗死体积并抑制 MMP-9 活性,其中 MCAO 前 30 分钟单次给予 100 mg/kg 剂量可使梗死体积减少 39%,而 MCAO 前 30 分钟及 MCAO 后 3 小时各给予一次 100 mg/kg 的两次给药可使梗死体积减少 40%。
KB-R7785 (100 mg/kg;皮下注射;每日 2 次;持续 4 周) 可显著降低胰岛素抵抗 KKAy 小鼠的血浆葡萄糖和胰岛素水平,并抑制 LPS (MS-X54539) 诱导的 TNF-α 产生,提示其可改善胰岛素敏感性。
KB-R7785 (2 mg;腹腔注射;每日 1 次;持续 21 天;剂量 2 mg) 可提高致死性急性移植物抗宿主病 (GVHD) 小鼠的存活率,消除体重下降,预防多个组织中 GVHD 相关的组织病理学损伤。
KB-R7785 (30-100 mg/kg;腹腔注射;单次给药) 在 100 mg/kg 剂量下可对致死性内毒素休克小鼠提供存活保护,其作用机制为显著降低血清 TNF-α 水平。
KB-R7785 (2 mg;皮下注射) 可通过抑制可溶性 TNF-α 的释放,预防小鼠致死性内毒素休克,但同时会降低宿主对 Listeria monocytogenes 感染的抵抗力 (在亚致死性感染中死亡率 >60%,且器官细菌载量升高),且不会损伤获得性抗李斯特菌免疫。

Animal Model: ICR mice (male, 18-22 g, permanent focal cerebral ischemia induced by intraluminal middle cerebral artery occlusion)
Dosage: 30, 100 mg/kg
Administration: s.c.; single injection; two injections
Result: Significantly reduced MMP-9 activity with single 100 mg/kg dose administered 30 minutes before MCAO compared to vehicle.
Reduced infarct volume by 12% and reduced indirect infarct volume to 60.2% of contralateral hemispheric volume with single 30 mg/kg dose administered 30 minutes before MCAO compared to vehicle.
Reduced infarct volume by 39% and reduced indirect infarct volume to 49.3% of contralateral hemispheric volume with single 100 mg/kg dose administered 30 minutes before MCAO compared to vehicle.
Reduced infarct volume by 40% with two 100 mg/kg doses administered at 30 minutes before and 3 hours after MCAO compared to vehicle.
Reduced infarct volume by 26% with two 100 mg/kg doses administered at 1 hour and 4.5 hours after MCAO compared to vehicle.
Had no significant effect on mean arterial blood pressure, regional cerebral blood flow, blood gas levels, rectal temperature, or plasma glucose levels compared to vehicle.
Animal Model: KKA/Ya Jcl mice (male, 11 weeks old, spontaneous insulin-resistant model)
Dosage: 30, 100 mg/kg
Administration: s.c.; twice daily; 4 weeks
Result: Did not affect body weight, plasma glucose levels, plasma insulin levels, or LPS-induced plasma TNF-α levels at 60 mg/kg/day.
Did not affect body weight at 200 mg/kg/day.
Significantly decreased plasma glucose levels after 3 weeks of treatment at 200 mg/kg/day.
Significantly decreased plasma insulin levels at the end of the treatment period at 200 mg/kg/day.
Significantly inhibited LPS-induced increases in plasma TNF-α levels at 200 mg/kg/day.
Rendered basal plasma TNF-α levels undetectable in all groups.
Animal Model: (BALB/c × C57BL/6)F1 mice (CBF1; H-2b/d) (six-week-old female; lethal acute GVHD induced by intravenous injection of 1×108 C57BL/6 spleen cells on day 0 and day 7)
Dosage: 2 mg
Administration: i.p.; daily; 21 days
Result: Achieved a 90% survival rate (9 of 10 mice survived indefinitely).
Prevented significant weight loss through day 21, matching the weight of age-matched normal mice.
Reduced serum TNF-α levels to undetectable (<10 pg/mL) on day 7.
Minimized or eliminated hepatic periportal mononuclear cell infiltration and fibrosis, intestinal villi flattening and crypt elevation, splenic lymphoid atrophy, and bone marrow hematopoietic cell atrophy.
Maintained a stable chimeric state with host-derived splenocyte subpopulations including 4.4×107 CD4+ T cells, 4.2×107 CD8+ T cells, and 7.3×107 B220+ B cells, and donor-derived subpopulations including 3.8×107 CD4+ T cells, 4.8×107 CD8+ T cells, and 6.0×107 B220+ B cells on day 14.
性状 固体
颜色 White to off-white

化学信息

分子量 349.42
分子式 C18H27N3O4
CAS No. 168158-16-5

储存&溶解度

储存方式

4°C, protect from light, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 20 mg/mL (57.24 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.8619 mL14.3094 mL28.6189 mL71.5471 mL
5 mM0.5724 mL2.8619 mL5.7238 mL14.3094 mL
10 mM0.2862 mL1.4309 mL2.8619 mL7.1547 mL
15 mM0.1908 mL0.9540 mL1.9079 mL4.7698 mL
20 mM0.1431 mL0.7155 mL1.4309 mL3.5774 mL
25 mM0.1145 mL0.5724 mL1.1448 mL2.8619 mL
30 mM0.0954 mL0.4770 mL0.9540 mL2.3849 mL
40 mM0.0715 mL0.3577 mL0.7155 mL1.7887 mL
50 mM0.0572 mL0.2862 mL0.5724 mL1.4309 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础